CONSTELLIUM SE (CSTM) Spending and interest coverage
- R&D / revenue · 12 months: Value 0.57%; Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 0.57% | Research and development expense / revenue. Period ending 2026-03-31. $51.00M ÷ $8.93B × 100 ≈ 0.57% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 51.00M USD | Research and Development Expense |
| Revenue | 8.93B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | |
| Operating income | (m) | |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $51.00M | $8.93B | (m) | (m) | (m) | 0.57% | (m) | (m) | (m) |
| 2025-12-31 | $51.00M | $8.45B | (m) | (m) | (m) | 0.60% | (m) | (m) | (m) |
| 2025-09-30 | $47.00M | $7.97B | (m) | (m) | (m) | 0.59% | (m) | (m) | (m) |
| 2025-06-30 | $46.00M | $7.61B | (m) | (m) | (m) | 0.60% | (m) | (m) | (m) |
| 2025-03-31 | $47.00M | $7.43B | (m) | (m) | (m) | 0.63% | (m) | (m) | (m) |
| 2024-12-31 | $49.00M | $7.33B | (m) | (m) | (m) | 0.67% | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $52.00M | $7.83B | (m) | (m) | (m) | 0.66% | (m) | (m) | (m) |
| 2022-12-31 | $46.00M | $8.53B | (m) | (m) | (m) | 0.54% | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aqua Metals, Inc. (AQMS) | United States | $0.009B | -0.64 |